Phase II trial in treatment of gastrointestinal fistulas with endoscopic injection of an alpha-cyanoacrylate monomer

Phase II trial in treatment of gastrointestinal fistulas with endoscopic injection of an alpha-cyanoacrylate monomer - Phase II trial in treatment of gastrointestinal fistulas with endoscopic injection of an alpha-cyanoacrylate monomer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018486

Enrollment

Registered

2015-08-01

Start date

2015-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointetinal fistulas

Interventions

Endoscopic injection of an alpha-cyanoacrylate monomer

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with intractable gastrointestinal fistulas 2) No severe disturbance of liver function and renal function 3) Written informed consent

Exclusion criteria

Exclusion criteria: 1) Patients with esophagotracheal fistulas 2) Patients with bile duct fistulas 3) Patients with pancreatic duct fistulas 4) Doctor's decision not to register to this regimen

Design outcomes

Primary

Measure	Time frame
Incidence of postprocedural complication	—

Secondary

Measure	Time frame
Incidence of fistulas closure Postoperative course Late complications	—

Countries

Japan

Contacts

Public ContactToshiyasu Ojima

Wakayama Medical University Second Department of Surgery

tojima@wakayama-med.ac.jp073-441-0613

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026